Early phase clinical trials are subject to complex regulation and red tape. The approval process is lengthy, confusing, and never guaranteed.
Established life sciences companies have greater brand recognition and existing relationships, making it harder for startups to gain traction and success.
Medtech and Biopharma startups often struggle to secure access to healthcare providers. Many hospitals aren’t willing to participate in clinical trials using new medical products.
Quickly recruiting patients for early-phase clinical trials is close to impossible. Potential patients are often reluctant, have too many options, or are ineligible.
Medtech and Biopharma startups often lack the financial resources and infrastructure to manage their trials, recruit patients, and collect data to analyze.
bioaccess® is your trusted partner for cost-effective, fast, and high-quality early-phase clinical research across Latin America, Eastern Europe, Australia, and beyond. We specialize in supporting startups and innovators with both medical device and biopharmaceutical clinical trials, combining deep expertise in Medtech and Biopharma to meet your unique needs. Our extensive global network and experience enable us to deliver seamless, multi-country trial management with dependable and timely outcomes.
At bioaccess®, we are more than a Medtech CRO—we are a comprehensive clinical research organization dedicated to advancing your projects across diverse regions and therapeutic areas. Collaborate with us to benefit from exceptional guidance, robust support, and the confidence that comes from partnering with a CRO committed to your success on a truly international scale.
bioaccess® will quickly and reliably deliver regulatory approval, clinical research site activation, patient recruitment, and trial data.
We connect innovative Medtech and Biopharma startups with top-ranked clinical research sites in Latin America, Eastern Europe, and Australia, bringing certainty in:
✔️ Moving to the next phase (an FDA IDE/IND pivotal/phase III study)
✔️ Raising funds
✔️ A successful exit